SBIR/STTR Research Award
THE GOAL OF THIS RESEARCH PROGRAM IS TO DEVELOP A SELF-ADMINISTERED INTRANASAL TLR4 AGONIST TO TREAT ALLERGIC RHINITIS. UNLIKEANTIGEN-SPECIFIC THERAPY
Award amount
$1,836,453Program and phase
SBIR · Phase II – Direct to Phase IIAward year
2021Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- INIMMUNE CORPoration
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- EF8AMXMGG8W5
- Solicitation number
- PHS2021-1
- Topic code
- 91
Research abstract
The goal of this project is to develop an intranasal TLR4 agonist to treat allergic rhinitis. Such treatment has the potential to provide short-term symptom control as well as long-term disease remission via allergen dependent T and B cell memory responses.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- PRODUCTION OF SYNTHETIC ADJUVANT SYSTEM (SAS): A SYNERGISTIC COMBINATION OF SYNTHETIC ADJUVANT COMPONENTS
- Novel synthetic TLR4 agonists
- Novel synthetic TLR4 agonists
- Discovery of new small molecule TLR4 agonists for the treatment of allergic rhinitis
Research funding history
5 SBIR/STTR records share this UEI (2018–2021). Reported award amounts total $5,615,672. Reported amounts are not federal obligations.
Phases: Phase II – Direct to Phase II, Phase I, Phase II
Agencies: Department of Health and Human Services